AccuStem

Our mission at AccuStem is to optimize outcomes for all patients with cancer across the globe. $ACUT

[AccuStem @AccuStem]

AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP). This pilot study agreement with NSABP is to evaluate StemPrintER in a subset of patients from the B-32 cohort. This evaluation will enable the two groups to then confirm the predictive capabilities of StemPrintER across the full study cohort. $ACUT
https://t.co/vpsR1QpuKf

[Virtual Investor Conferences @RIConferences]

Join @ZacksSmallCap Life Sciences Virtual Investor Forum starting at 9:30am ET.
Presentations by: @ampliatx, @kelyniam, @unitedhealthinc, @PetVivo, Dermata, @Hemostemix_Inc, @LipellaPharma, @inmedpharma, @AccuStem, @Sigyn_inc & @PercheronTxL https://t.co/fzKR3x7sOR

[AccuStem @AccuStem]

AccuStem Sciences and @EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning. “We continue to see significant progress with the MSC technology transfer into EmeritusDX���s laboratories,” $ACUT
https://t.co/OVki5s0jjT

[AccuStem @AccuStem]

AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th.
AccuStem CEO, Wendy Blosser, will present live at the Life Sciences Virtual Investor Forum hosted by https://t.co/VtaWy6emCa
$ACUT #CEO
Sign up via the link below:
https://t.co/2kYVfKofx5

[AccuStem @AccuStem]

Today Accustem announced that the Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 2,400 ACUT shares in the open market. This brings his total holding to 6,502,400 shares. $ACUT
https://t.co/Oer5Se4Y6W

[AccuStem @AccuStem]

Today Accustem announced that the Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 8,991 ACUT shares in the open market. This brings his total holding to 6,500,000 shares. $ACUT
https://t.co/G3jBOB6ezE

[AccuStem @AccuStem]

Exciting news for AccuStem and @EmeritusDX - we are expanding our strategic partnership beyond StemPrintER to operationalize and commercialize the MSC test for clinical use in lung cancer screening in 2026! $ACUT
https://t.co/XZKO3X7b9i

[AccuStem @AccuStem]

AccuStem Sciences, Inc. Announces Chairman Purchase of Shares.
Chairman, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased 5,000 ACUT shares in the open market. This brings his total holding to 4,915,759 shares. $ACUT
https://t.co/BUkeQIgcJp

[AccuStem @AccuStem]

We are pleased to announce the completion of a collaborative agreement that will allow AccuStem to access blood samples from the prospective, multi-center RISP trial. $ACUT
https://t.co/zao9OWvBNw

[AccuStem @AccuStem]

AccuStem Sciences, Inc. Announces Chairman Purchase of Shares.
Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 38,000 ACUT shares in the open market. This brings his total holding to 4,910,759 shares. $ACUT
https://t.co/so4Gfy8bId

[AccuStem @AccuStem]

AccuStem Sciences, Inc. Announces Chairman Purchase of Shares.
Chairman, Gabriele Cerrone, has recently purchased an additional 152,802 ACUT shares in the open market. This brings his total holding to 4,872,759 shares. $ACUT
https://t.co/3Usw3Rs7HE

[AccuStem @AccuStem]

We believe based on the most recent data published in the Lancet that the blood-based MSC test will serve a critical role in enhancing the accuracy of standard LDCT screening for those at high risk of lung cancer. $ACUT
Read the journal article here: https://t.co/5Vm12ItNTu

[AccuStem @AccuStem]

AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States. $ACUT
Ready the story here: https://t.co/iI43USK8U6

[AccuStem @AccuStem]

We believe our test will provide more definitive diagnoses and peace of mind for patients beyond low dose CT screening alone, with the added benefit of saving costs to the healthcare system. $ACUT
Learn more about our proprietary test here: https://t.co/5D5m6x5L4y 2/2

[AccuStem @AccuStem]

Exciting news for AccuStem- we have acquired the license to the MSC lung cancer screening test! $ACUT
Read the story here: https://t.co/pNYImDehXX 1/2

[AccuStem @AccuStem]

AccuStem Sciences Announces Acquisition of Proprietary MSC Lung Cancer Screening Test.
The blood-based test evaluates 24 micro RNAs to improve the diagnostic performance of low-dose computed tomography (LDCT) in patients with pulmonary nodules.
$ACUT
https://t.co/pNYImDehXX

[AccuStem @AccuStem]

Today we announced that the Chairman of AccuStem, Gabriele Cerrone has purchased 100,000 shares on the open market. This brings his total holding to 4,719,957 shares. $ACUT
https://t.co/GUSnv0rxPQ

[AccuStem @AccuStem]

Thank you for covering our great news @MedicalTechMag on our next step towards validation and in the reimbursement process.
AccuStem signs product development agreement with @EmeritusDX
https://t.co/jocn6vgogt $ACUT

[AccuStem @AccuStem]

We are excited to announce a partnership with an emerging leader in diagnostics, @EmeritusDX. Together, we will build a stronger foundation of data for #StemPrintER and work to change the way #breastcancer and other types of #cancer are treated. $ACUT https://t.co/qCtyoIMRed

[AccuStem @AccuStem]

Today we announced that we have extended our partnership with @IEOufficiale to advance our approach to surgical utility of our StemPrintER test. StemPrintER is shown to be highly prognostic for patients at high risk of #breastcancer recurrence. $ACUT
https://t.co/PMX1no5Yg4